Continuous Glucose Monitoring Versus Capillary Point-of-Care Testing for Inpatient Glycemic Control in Type 2 Diabetes Patients Hospitalized in the General Ward and Treated With a Basal Bolus Insulin Regimen
Ana M Gómez, Guillermo E Umpierrez, Oscar M Muñoz, Felipe Herrera, Claudia Rubio, Pablo Aschner, Richard Buendia, Ana M Gómez, Guillermo E Umpierrez, Oscar M Muñoz, Felipe Herrera, Claudia Rubio, Pablo Aschner, Richard Buendia
Abstract
Background: Continuous glucose monitoring (CGM) may improve the management of patients with type 2 diabetes hospitalized in the general ward by facilitating the detection of hyper- and hypoglycemic episodes. However, the lack of data on the accuracy and safety of CGM have limited its application.
Methods: A prospective pilot study was conducted including 38 patients hospitalized in the general ward with a known diagnosis of type 2 diabetes mellitus (DM) and hyperglycemic individuals without a history of DM with a blood sugar of 140-400 mg on admission treated with a basal bolus insulin regimen. Inpatient glycemic control and the incidence of hypoglycemic episodes were compared between detection by CGM of interstitial fluid for up to 6 days and point-of-care (POC) capillary blood glucose monitoring performed pre- and postprandially, before bedtime and at 3 am.
Results: No differences in average daily glucose levels were observed between CGM and POC (176.2 ± 33.9 vs 176.6 ± 33.7 mg/dl, P = .828). However, CGM detected a higher number of hypoglycemic episodes than POC (55 vs 12, P < .01). Glucose measurements were clinically valid, with 91.9% of patients falling within the Clarke error grid A and B zones.
Conclusions: Our preliminary results indicate that the use of CGM in type 2 patients hospitalized in the general ward provides accurate estimation of blood sugar levels and is more effective than POC for the detection of hypoglycemic episodes and asymptomatic hypoglycemia.
Keywords: continuous glucose monitoring; hyperglycemia; hypoglycemia; point-of-care testing.
Conflict of interest statement
Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AMG reports speaker fees from NovoNordisk, Elli Lilly, MSD, Novartis, and Medtronic and research grants from Medtronic, Novartis, and Abbott. CR receives fees for a patient education program with NovoNordisk and insulin pump patient training with Medtronic. PA has participated in advisory boards and has received speaker fees from AstraZeneca, BMS, Boehringer, GSK, Jansen, J&J, Lilly, MSD, Novartis, and Sanofi and has participated in original research involving Sitagliptin and insulin Glargine.
© 2015 Diabetes Technology Society.
Figures
Source: PubMed